Welcome to our dedicated page for Novo-Nordisk A S SEC filings (Ticker: NONOF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for NOVO NORDISK A/S B NEW (NONOF) provides access to disclosures filed by Novo Nordisk A/S as a foreign issuer. These filings give detailed insight into the company that underlies NONOF, including its therapeutic focus, clinical programmes, governance decisions and insider transactions.
Through Form 6-K and other submissions, Novo Nordisk reports material developments such as FDA approval of the Wegovy pill, a once-daily oral semaglutide 25 mg tablet for weight management and reduction of major adverse cardiovascular events in adults with obesity or overweight and specific cardiovascular conditions. Filings also describe the OASIS phase 3 programme in obesity, phase 2 results for amycretin in type 2 diabetes, and outcomes of the evoke and evoke+ phase 3 trials in Alzheimer’s disease.
Regulatory documents further cover corporate matters. Extraordinary general meeting resolutions detail changes in the Board of Directors and the composition of committees like the Audit, Remuneration, People and Governance, and Research & Development Committees. Separate filings disclose trading in Novo Nordisk shares by board members, executives and associated persons, in line with market abuse rules, providing transparency around insider activity in Novo Nordisk B shares listed on Nasdaq Copenhagen and ADRs listed on the New York Stock Exchange.
On Stock Titan, these SEC filings are updated from EDGAR and can be paired with AI-powered summaries that explain the key points in plain language. Users researching NONOF can use this page to quickly understand what Novo Nordisk reports in its official documents, from clinical data and product approvals to governance changes and insider transactions, without reading every page of each filing.
Novo Nordisk A/S reports progress on its ongoing share repurchase programme. Since 4 February 2026, the company has bought back 9,162,992 B shares at an average price of DKK 261.91, for a total of DKK 2,399,878,368.
This activity is part of a broader plan to repurchase up to DKK 15 billion of B shares over 12 months from 4 February 2026. Following the latest transactions, Novo Nordisk holds 26,552,791 B shares as treasury shares, equal to 0.6% of its 4,465,000,000 total A and B shares.
Novo Nordisk A/S has updated and restated its Articles of Association following approval at the Annual General Meeting on 26 March 2026. The Articles set the company’s share capital at DKK 446,500,000, divided into A share capital of DKK 107,487,200 and B share capital of DKK 339,012,800, with shares of DKK 0.01 or multiples.
A shares are non-negotiable, may have share certificates and carry 10 votes per DKK 0.01, while B shares are negotiable, issued through a central securities depository and carry 1 vote per DKK 0.01. Detailed pre‑emptive rights and transfer restrictions apply to A shares, whereas B shares are freely transferable.
Until 1 April 2028, the Board of Directors is authorised to increase the share capital by up to a nominal DKK 44,650,000, both with and without pre‑emptive rights, mainly via B shares at market price and potentially for non‑cash contributions. The Articles also describe general meeting procedures, allow partially or fully electronic meetings, define a Board of 4–10 shareholder‑elected members plus employee representatives, and formalise an indemnification scheme for directors and executive management. Dividend distribution gives priority returns to A and then B shares, and in a dissolution B share capital is repaid at nominal value before A share capital, with any remaining proceeds shared proportionally.
Novo Nordisk reports that the US FDA has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly long-acting basal insulin for adults with type 2 diabetes, used along with diet and exercise to improve blood sugar control.
The approval is based on the ONWARDS phase 3a programme in about 2,680 adults, where once-weekly Awiqli® was compared with daily basal insulin and met its primary goal of lowering HbA1c, with an overall safety profile consistent with the basal insulin class.
Novo Nordisk plans to launch Awiqli® in the FlexTouch® device in the US in the second half of 2026. Awiqli® is now approved in the US, EU and 13 additional countries, expanding the company’s diabetes treatment portfolio.
Novo Nordisk A/S held its Annual General Meeting, where shareholders approved the statutory Annual Report 2025 and the distribution of profits. The total dividend for 2025 was set at DKK 11.70 per A and B share, consisting of an interim dividend of DKK 3.75 already paid in August 2025 and a final dividend of DKK 7.95 to be paid in March 2026.
Shareholders re-elected Cees de Jong as vice chair and several existing board members, and elected Helena Saxon, Jan van de Winkel and Ramona Sequeira to the Board. Deloitte was re-appointed as auditor.
The Board received authorisation until the 2027 AGM to repurchase up to 10% of the share capital, subject to a 10% holding limit, and an extension to increase share capital until 1 April 2028 by up to nominally DKK 44,650,000. Committee compositions were updated, and Poul Weihrauch will join as a Board observer with the intention of nomination in 2027.
Novo Nordisk A/S provides an update on its ongoing share repurchase programme. The company plans to buy back B shares for up to DKK 15 billion during a 12‑month period beginning 4 February 2026, including a sub-programme of up to DKK 3.8 billion running from 4 February 2026 to 4 May 2026.
As of 20 March 2026, Novo Nordisk has repurchased a total of 7,847,992 B shares at an average price of DKK 266.53 per share, for a total transaction value of DKK 2,091,696,255. Following these transactions, Novo Nordisk holds 25,237,791 B shares as treasury shares, equal to 0.6% of the 4,465,000,000 A and B shares outstanding, including treasury shares.
Novo Nordisk reports that the US FDA has approved Wegovy® HD, a once-weekly injectable semaglutide 7.2 mg dose, to reduce excess body weight and maintain long-term weight reduction. The FDA also granted a Commissioner’s National Priority Voucher, highlighting the therapy’s importance for US health priorities.
The accelerated approval is supported by the STEP UP phase 3 programme. In the STEP UP trial in adults with obesity, semaglutide 7.2 mg delivered a 20.7% mean weight loss, and 31.2% of participants achieved at least 25% weight loss. In the STEP UP T2D trial in adults with obesity and type 2 diabetes, mean weight loss reached 14.1%. Safety and tolerability were consistent with the known profile of semaglutide.
Novo Nordisk plans to launch Wegovy® HD in a single-dose pen in the US in April 2026. The 7.2 mg dose is already approved for adults with obesity in the EU and UK, and regulatory decisions on the single-dose pen in those regions are expected in the second half of 2026.
Novo Nordisk A/S provides an update on its ongoing share repurchase programme. The company plans to buy back up to DKK 15 billion of B shares over the 12‑month period starting 4 February 2026, including up to DKK 3.8 billion between 4 February and 4 May 2026.
As of 13 March 2026, Novo Nordisk has repurchased 6,577,992 B shares at an average price of DKK 271.14, for a total of DKK 1,783,540,174. After these transactions, it holds 23,967,791 B shares as treasury shares, equal to 0.5% of its 4,465,000,000 total A and B shares.
Novo Nordisk A/S reports progress on its 2026 share repurchase programme. As part of a broader plan to buy back up to DKK 15 billion of B shares over 12 months from 4 February 2026, the company has been actively repurchasing shares in early March.
As of 6 March 2026, Novo Nordisk has repurchased 5,334,992 B shares at an average price of DKK 276.06, for a total of DKK 1,472,797,094. Following these transactions, it holds 22,724,791 B shares as treasury shares, equal to 0.5% of its total 4,465,000,000 A and B shares.
Novo Nordisk A/S reports that its employees have completed the election of new employee representatives to the company’s Board of Directors. These representatives are elected for a four-year term and, under Danish law, employee-elected members may make up half of the shareholder-elected board members.
The newly elected employee representatives will join the Board after the annual general meeting on 26 March 2026, when current employee board members Liselotte Hyveled and Tanja Villumsen, who did not run for re-election, will step down. Employee-elected directors have the same rights and responsibilities as shareholder-elected directors.
Novo Nordisk A/S provides an update on its ongoing share repurchase programme. The company is running an overall buyback of up to DKK 15 billion over 12 months beginning 4 February 2026, aimed at repurchasing B shares.
Under the specific programme running from 4 February 2026 to 4 May 2026, Novo Nordisk plans to buy back up to DKK 3.8 billion of B shares. As of 27 February 2026, it has repurchased 4,045,000 B shares at an average price of DKK 286.95, for a total of DKK 1,160,693,639.
Following these transactions, Novo Nordisk holds 21,434,799 B shares as treasury shares, representing 0.5% of its share capital. The company’s total share capital consists of 4,465,000,000 A and B shares, including treasury shares.